Skip to content

Maurizio Pompili

4 papers in the library · 212 citations · publishing 2018-2025

Papers

Sort Most recent Most cited

Efficacy of Intranasal Esketamine in Treatment-Resistant Depression: A Six-Month Real-World Follow-Up Study of Depressive Symptoms, Hopelessness, and Suicide Risk.

Human Psychopharmacology July 1, 2025 Maurizio Pompili, Maria Anna Trocchia, Ludovica Longhini et al. 3 citations

Treatment-resistant depression is one of the most significant clinical challenges in psychiatric practice. The primary aim of the present study was to assess the efficacy and tolerability of intranasal esketamine on depressive symptoms in a real-world outpatient setting. A secondary objective was to explore the potential benefits of intranasal esketamine on hopelessness and suicide risk...

DOI: 10.1002/hup.70008 (opens in new tab) Full text (opens in new tab) Esketamine Treatment-resistant depression Suicide prevention Suicide risk +2

Can dextromethorphan-bupropion reduce mental pain in depressed individuals? A generating hypothesis overview perspective.

Annals of General Psychiatry March 17, 2025 Maurizio Pompili, Isabella Berardelli, Denise Erbuto et al.

Globally, major depressive disorder, or MDD, is a leading cause of disability. It negatively impacts social interactions and significantly limits daily functioning, ultimately reducing life satisfaction. The prevalence rate is about twice as high in women as in males. It is believed that the genesis of major depressive disorder is complicated and includes biological, genetic, environmental, and...

DOI: 10.1186/s12991-025-00549-x (opens in new tab) Full text (opens in new tab) Major depressive disorder Antidepressant Dextromethorphan-bupropion Mental pain +1

An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine

Current Topics in Medicinal Chemistry January 31, 2020 Domenico de Berardis, Carmine Tomasetti, Maurizio Pompili et al. 38 citations

BACKGROUND: A research on mood disorder pathophysiology has hypothesized abnormalities in glutamatergic neurotransmission, by suggesting further investigation on glutamatergic N-methyl-Daspartate (NMDA) receptor modulators in treating Major Depressive Disorder (MDD). Esketamine (ESK), an NMDA receptor antagonist able to modulate glutamatergic neurotransmission has been recently developed as an...

DOI: 10.2174/1568026620666200131100316 (opens in new tab) Treatment-resistant depression Major depressive disorder Glutamatergic Suicidal ideation +9

Eradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors

International Journal of Molecular Sciences September 23, 2018 Domenico de Berardis, Michele Fornaro, Alessandro Valchera et al. 171 citations

Despite the continuous advancement in neurosciences as well as in the knowledge of human behaviors pathophysiology, currently suicide represents a puzzling challenge. The World Health Organization (WHO) has established that one million people die by suicide every year, with the impressive daily rate of a suicide every 40 s. The weightiest concern about suicidal behavior is how difficult it is...

DOI: 10.3390/ijms19102888 (opens in new tab) Ketamine Anxiety Suicidal ideation Mood disorders +5